Related Experiment Videos
Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents
George D Hartman1, Mark E Fraley, Mark T Bilodeau
1Department of Medicinal Chemistry, Merck Research Laboratories, WP14-2, West Point, PA 19486, USA. george_hartman@merck.com
Abstract:
A variety of data accumulated during the past 10 years indicates that vascular endothelial growth factor-mediated angiogenesis is a key process in the growth of solid tumours. Efficacious and specific modulation of that signalling event through the inhibition of the cognate tyrosine kinase kinase insert domain-containing receptor (Flk-1) has been reported. A variety of small molecule kinase-domain-containing receptor kinase inhibitors, including SU-5416, SU-6668, PTK-787, midostaurin, ZD4190 and ZD6474, have progressed to the clinical testing stage and this has allowed the direct and critical inspection of preclinical and clinical behaviour. The variety of potency, kinase selectivity and pharmacokinetic profiles offered by this group of compounds is providing important guidance for the efficacious use of these agents today and the design of second and third generation compounds for the future.
Insights
Inhibiting vascular endothelial growth factor receptor (Flk-1) with small molecules is a promising strategy against solid tumors. Clinical trials of these kinase inhibitors are guiding current use and future drug development.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Vascular endothelial growth factor (VEGF)-mediated angiogenesis is crucial for solid tumor growth.
- Inhibiting the VEGF receptor tyrosine kinase, kinase insert domain-containing receptor (Flk-1), is a validated anti-cancer strategy.
Purpose of the Study:
- To review the clinical progress and therapeutic potential of small molecule Flk-1 inhibitors.
- To analyze the preclinical and clinical data of various Flk-1 inhibitors.
Main Methods:
- Review of accumulated data over the past 10 years.
- Analysis of clinical trial data for small molecule Flk-1 inhibitors.
- Evaluation of compound potency, kinase selectivity, and pharmacokinetic profiles.
Main Results:
- Several small molecule Flk-1 inhibitors (e.g., SU-5416, SU-6668, PTK-787, midostaurin, ZD4190, ZD6474) have advanced to clinical testing.
- These inhibitors demonstrate varied potency, selectivity, and pharmacokinetic properties.
- Clinical and preclinical data provide insights into their behavior and efficacy.
Conclusions:
- Small molecule inhibition of Flk-1 is a viable therapeutic approach for solid tumors.
- The diverse profiles of current inhibitors inform their clinical application and the design of next-generation agents.
- Continued research and development of Flk-1 inhibitors hold promise for future cancer treatment.